
PTI
Healthcare · Biotechnology · $2.9M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2020
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 16, 2020 | After the close | -0.18 | -0.11 | +38.6% |
| Aug 6, 2020 | After the close | -0.21 | -0.17 | +20.0% |
| May 15, 2020 | After the close | -0.26 | -0.19 | +25.5% |
| Mar 10, 2020 | After the close | -0.29 | -0.23 | +20.0% |
| Nov 7, 2019 | After the close | -0.41 | -0.25 | +38.5% |
| Aug 7, 2019 | After the close | -0.38 | -0.39 | -3.5% |
| May 8, 2019 | After the close | -0.36 | -0.28 | +22.2% |
| Mar 8, 2019 | After the close | -0.40 | -0.36 | +9.3% |
| Nov 6, 2018 | After the close | -0.43 | -0.50 | -15.4% |
| Aug 8, 2018 | After the close | -0.36 | -0.43 | -19.4% |
| May 9, 2018 | After the close | -0.54 | -0.32 | +40.4% |
| Mar 14, 2018 | After the close | -0.61 | -0.50 | +18.0% |
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements…